Kaplan Fox & Kilsheimer LLP Encourages Investors of The Simply Good Foods Company (NASDAQ: SMPL) to Contact the Firm Regarding Potential Securities Law Violations

Simply Good Foods is under investigation by Kaplan Fox & Kilsheimer for potential securities violations following major post-acquisition issues tied to OWYN. The company disclosed a “quality issue” in OWYN from pea protein raw material sourcing and later reported Q2 2026 net sales down 9.4% ($326.0M), alongside a $249.0M non-cash impairment charge (including $187.0M for OWYN). Shares reacted sharply previously, falling 17.35% to $20.63 on Oct. 23, 2025 and 18.11% to $11.80 on Apr. 9, 2026, underscoring the negative fundamentals and litigation overhang.

Analysis

This is less a standalone litigation event than a confirmation that the market is still repricing a broken acquisition narrative. The first-order damage is already reflected in the chart; the second-order risk is that a formal complaint can keep a low-multiple consumer name under a litigation discount for quarters, especially if the alleged disclosure gap is tied to pre-close sourcing or diligence failures. That matters because it raises the probability of governance-driven de-rating, higher D&O expense, and management distraction just as the core brands need stabilization.

The bigger issue is competitive: if OWYN shelf space or velocity remains impaired, the share loss likely accrues to faster-moving protein shake incumbents rather than the broader food aisle. BRBR is the cleanest beneficiary because retailers tend to reallocate facings to the brand that can fill volume immediately; once planograms reset, regaining shelf space is slow and promotional. The market may be underestimating how impairment charges become self-fulfilling when retailers and distributors interpret them as a signal that the brand is already losing relevance.

Over the next 1-3 months, the real catalyst is not the attorney letter but whether management can prove sequential stabilization in scanner data and gross margin. If not, the litigation overhang will compound a fundamental short. Over 6-18 months, the question is whether this becomes a one-off legal expense or evidence that the acquired brand base is structurally weaker than booked, which would justify a lower terminal multiple even if the lawsuit settles for an insurance-covered amount.

Key Decisions for Investors

• Short SMPL on any relief rally over the next 1-4 weeks; treat the attorney press release as a sentiment fade rather than a catalyst to chase. Use a tight stop if the stock reclaims the post-impairment breakdown area and the next print shows stable OWYN/Atkins trends.
• Pair trade: long BRBR / short SMPL for the next 1-3 quarters to express shelf-share migration in protein RTD. Risk/reward is favorable if scanner data or retailer commentary confirms that premium protein facings are being reallocated away from OWYN.
• Buy a limited-risk SMPL put spread into the next earnings date only if implied volatility remains below the realized move from the last two events; this is a good way to monetize a potential formal complaint or guidance cut without taking open-ended litigation risk.
• Do not add to SMPL until management provides hard evidence of stabilization in net sales and margin, not just legal rebuttals. Falsifier for the short thesis: two consecutive quarters of improving organic sales in OWYN plus no new reserve/build or SEC escalation.